Myriad Genetics Reports Fiscal First-Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Myriad Genetics (MYGN) PT Raised to $47 at Piper Jaffray
November 4, 2015 8:50 AM ESTPiper Jaffray analyst William Quirk reiterated an Overweight rating and boosted his price target on Myriad Genetics (NASDAQ: MYGN) to $47.00 (from $45.00) following Q1 beat.
Quirk commented, "Myriad's 1Q16 revenue increased 9% yoy to $183.5M, above consensus of $177.9M (PJC: $177.6M). Adjusted EPS of $0.41 was above consensus'... More
Myriad Genetics (MYGN) PT Lifted to $42 at Mizuho Securities Post Q1; Remains Sidelined
November 4, 2015 7:57 AM ESTMizuho Securities analyst Eric Criscuolo bumped his price target on Myriad Genetics (NASDAQ: MYGN) to $42.00 (from $38.00) following results but remains on the sidelines with a Neutral rating.
Criscuolo commented, "We are upping our PT to $42 but remain on the sidelines. MYGN reported... More
Myriad Genetics (MYGN) PT Up to $46 at Leerink Partners After Solid Q1
November 4, 2015 7:21 AM ESTLeerink Partners analyst Dan Leonard lifted his price target on Myriad Genetics (NASDAQ: MYGN) to $46.00 (from $37.00) following solid Q1 results but maintained a Market Perform rating.
Leonard commented, "We are nudging up our FY16 estimates following MYGN's solid September quarter (F1Q),... More
Myriad Genetics (MYGN) Tops Q1 EPS by 6c
November 3, 2015 4:14 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $183.5 million versus the consensus estimate of $177.89 million.
Myriad Genetics sees FY2015 EPS of $1.60-$1.65, versus the consensus of $1.64. Myriad Genetics sees FY2015... More
